Psych Eval 3

profileGracenana
  • 4 hours ago
  • 10
files (2)

PsychEvalResponse3.docx

Discussion including at least one meaningful response to at least one of your peers’ Psych Evals should occur by Tuesday at 11:59 pm EST in weeks 4, 8, and 12. A meaningful response demonstrates critical thought. Refer to the Carlat and Kaplan & Kaplan texts for assistance. Posts that are perfunctory or only minimally meet all grading criteria do not necessarily qualify as “excellent” which would yield full points (100). This is true for both the initial post and the response post. One response post is considered to meet the criteria minimally.

STUDENT’S POST:

Psychiatric Evaluation 3

Demographic/Identifying Information

D.A. is a 22-year-old, single, Hispanic male who presents today for an initial psychiatric evaluation due to persistent social anxiety that has also been impacting his academic and social functioning. The source of information for this evaluation was from the patient’s personal report. No old medical records were available for review at this time. D.A. was able to give clear and chronological details of his symptoms and life events. This showed he has good insight into his condition and a strong motivation for treatment.

Subjective Data

Chief Complaint

“I feel uncomfortable around people.”

History of Presenting Illness

D.A. is a 22-year-old Hispanic male who presents to the clinic with social anxiety. He reported that his symptoms have been present since adolescence, but they have been getting worse after he left home and joined campus. D.A. admitted that he struggles with social situations and has great fear over being judged or experiencing humiliation and embarrassment from social interactions. He reported that he feels like everyone is always watching him and waiting for him to make a mistake whenever he is in public.

OLDCARTS Assessment

· Onset: Early adolescence, but symptoms have worsened in the past 2 years after starting college.

· Location: Cognitive, physical, and behavioral domains.

· Duration: Persistent all day.

· Character: His symptoms include fear of being evaluated in a negative manner, being seen as stupid or awkward, or being judged. He also experiences blushing, sweating, shakes, increased heart rate, and nausea whenever he finds himself in a public or social situation. D.A. also avoids social situations as much as possible.

· Aggravating Factors: Finding himself as the center of attention, meeting new people, speaking in front of groups, and situations where he feels he might be evaluated.

· Relieving Factors: Avoiding social situations provides temporary relief.

· Timing: Symptoms are present in anticipation of and during social situations.

· Severity: He rates his anxiety as 7/10 in social situations, increasing to 10/10 when he is required to speak in front of others. He states the symptoms are interfering with his ability to make friends and succeed in his academics.

Pertinent Negatives

· D.A. does not admit any suicidal thoughts, any homicidal thoughts, or any violent thoughts.

· He denies having any prior self-injurious behavior.

· He denies ever experiencing mania or hypomania.

· He denies having delusions, hallucinations, and paranoia.

· He does not have obsessions or compulsions.

· He has never experienced any panic attacks, but he describes being anxious in social settings.

· He denies any depression episodes.

· He denies any history of trauma or abuse.

Review of Systems

· General: Admits fatigue, especially after social situations. Denies fevers, chills, or night sweats. Denies any significant weight changes.

· Neurologic: Admits regular tension headaches and muscle tension. Denies tremors, seizures, or sensory changes.

· Psychiatric: Admits anxiety and low mood related to social isolation. Denies depressed mood or heavy sadness.

· Sleep: Admits initial insomnia due to anticipatory anxiety, especially when he has to engage in social interactions for the next day.

· Gastrointestinal: Admits experiencing nausea in social situations but denies vomiting, diarrhea, or constipation.

· Cardiovascular/Pulmonary: Admits experiencing palpitations and trembling whenever he is in social situations. He denies chest pains, tightness, or shortness of breath during these social situations. A.D. admits that his asthma is well-controlled and he only uses his albuterol inhaler occasionally.

· Endocrinologic: Denies experiencing heat or cold intolerance or excessive sweating during the night.

Past Psychiatric History

· D.A. denies any past psychiatric history, hospitalizations, or suicidal attempts.

· He has never experienced any kind of psychotherapy treatments.

· Psychotherapy: None.

· Hospitalizations: None.

· Suicide attempts: D.A. denies any history of suicidal thoughts, having an intent, plan, or attempts to end her life.

Previous Psychiatric Medications

· D.A. has never been on any psychiatric medication.

Current Medications

· Albuterol inhaler 90 mcg/actuation, 2 puffs inhaled every 4-6 hours as needed for asthma. Reports using it approximately 1-2 times per month.

· No psychiatric medications.

· No over-the-counter medications or supplements reported.

Substance Use/Addictive Behaviors

· Alcohol: Reports occasional social drinking, approximately 1-2 drinks per week when he does attend social events. Denies any history of blackouts, withdrawal symptoms, or problems related to alcohol use.

· CAGE Questionnaire: Negative.

· Caffeine: Takes approximately 4 cups of coffee per day.

· Tobacco/Nicotine: Denies use.

· Illicit Drugs: Has no history of illicit drug use, which includes marijuana, cocaine, stimulants, opiates, or synthetic drugs.

· Misuse of Prescription Medication: Denies any misuse of his prescription medication or other people's medications.

· Addictive Behaviors: No gambling, gaming, spending, or eating problems. No history of eating disorders.

Family Psychiatric History

· Mother (age 50): Reports his mother has a history of "shyness" and anxiety but was never formally diagnosed.

· Father (age 52): No known psychiatric history but is reported to be taking high amounts of alcohol.

· Sister (age 25): Has a history with depression, which has been treated with medication.

· Sister (age 18): Has a history with attention deficit hyperactivity disorder.

· The family has no known completed or attempted suicide.

Medical History

· Medical Illnesses: Reports a history of mild intermittent asthma, diagnosed in childhood. Reports it is well-controlled with albuterol as needed. No other chronic medical conditions.

· History of Medical Illness: Unremarkable.

· Surgical History: None.

· Allergies: No known drug or food allergies.

· Last Physical Exam: Reports having a physical exam approximately one year ago, which was unremarkable. No recent lab work available for review.

Psychosocial and Developmental History

· Childhood: Born and raised in Florida by his biological mother and father, who were immigrants. He reports having a stable and supportive family environment, and he is the middle of three children.

· Education: He is currently a senior in college, pursuing a bachelor's degree in business administration.

· Living Conditions: Lives in a dormitory on campus with one roommate. He has a good relationship with his roommate but still finds it difficult to socialize with others.

· Marital Relationships: Single.

· Children: None.

· Occupation: D.A. works part-time as a stock clerk at a retail store. He reports that he chose this job because it has minimal interaction with customers.

· Legal: None.

· Abuse: Denies any physical, sexual, or emotional abuse during childhood.

· Religious: Catholic but is not currently practicing.

Assets and Stressors

· Assets: He has a supportive family, good educational background, and motivation for treatment.

· Stressors: His college environment has high social demands, there is academic pressure, and he struggles with social isolation.

Objective Data

Mental Status Examination

· Appearance: D.A. is a 22-year-old Hispanic male with a slim build. He is well-groomed and dressed in casual but neat clothes that include jeans and a t-shirt. His appearance was as his stated age.

· Behavior: D.A. is cooperative but avoids eye contact during the interview, and he spends most of the time looking down or away. He shows mild psychomotor restlessness, as shown by him frequently shifting in his seat and fidgeting with his hands.

· Speech: D.A. has a fluent, coherent, and normal rate of speech. He speaks in a quieter volume but remains to be audible. There is no evidence of pressured speech, latency, or thought blocking.

· Affect and Mood: His affect is anxious and guarded, as evidenced by his tense posture and minimal facial expression. He describes his mood as “anxious and uncomfortable.” His affect is congruent with his reported mood.

· Thought Process: D.A. has a logical, linear, and goal-directed thought process. He is able to describe his concerns clearly and stays on topic.

· Thought Content: D.A. shows excessive thought content focused on the fear of negative evaluation, embarrassment, and humiliation in social situations. He denies any suicidal, homicidal, or violent thoughts. D.A. also denies any psychotic symptoms, and there are no obsessions or compulsions.

· Cognitive Assessment: D.A. is fully oriented to person, place, time, and situation (x4). His concentration is intact, as he was able to perform serial 7s without any problem. His short-term memory is intact, as he was able to recall 3/3 objects after 5 minutes. His long-term memory is intact. His fund of information is appropriate according to his education. His abstract thinking is intact, as he was able to understand simple proverbs like "honesty is the best policy." His insight is good as he realizes that his fear of judgment is exaggerated and he is seeking help. His judgment is intact as he is taking care of his studies and other responsibilities.

Physical/Vital Signs/Laboratory Data.

· Vital signs

· Blood Pressure: 119/78 mmHg (normal).

· Heart Rate: 77 bpm.

· Respiratory Rate: 25 breaths/min.

· Temperature: 98.1°F.

· O2 Sat: 94% on room air.

· Weight: 122 lb.

· Height: 5’6’’

· BMI: 19.7 kg/m²

· Physical Exam

· General: D.A. appears to be in good health. No pains, appearance anomalies, severe sickness, or any signs of underlying disease were present.

· Laboratory Testing: There are no lab tests reviewed during the current visit.

Assessment

Differential Diagnoses

1. Social Anxiety Disorder (F40.10):

Rationale: D.A. fulfills the DSM-5-TR diagnostic criteria for social anxiety disorder. He experiences strong fear in one or more social situations where there is an exposure to being watched by other people. D.A. also fears behaving in a manner that may lead to humiliation or embarrassment. His anxiety is almost always present in social situations. There is avoidance of social situations. His fear and anxiety are also disproportionate to the actual threat and have been persistent for at least 6 months. This also caused significant functional impairment in his social and academic performance (American Psychiatric Association, 2022).

2. Generalized Anxiety Disorder (F41.1):

Rationale: The patient reports anxiety, but his anxiety is specifically focused on social situations and fear of judgment, instead of being uncontrollable across multiple domains (American Psychiatric Association, 2022).

3. Avoidant Personality Disorder (F60.6):

Rationale: Avoidant Personality Disorder is characterized by symptoms of avoiding work or school because of fear of rejection, unwillingness to get involved with people, showing fear of shame in intimate relationships, and preoccupation with being rejected in social settings. D.A. shares some features with avoidant personality disorder, but his symptoms are episodic. He fits the criteria for social anxiety disorder more compared to avoidant personality disorder at this time (American Psychiatric Association, 2022).

4. Panic Disorder (F41.0):

Rationale: The patient denies a history of recurrent, unexpected panic attack symptoms like a pounding heart, shortness of breath, and chest tightness. His anxiety is specifically tied to social situations, and they do not occur spontaneously. This makes panic disorder less likely (American Psychiatric Association, 2022).

Diagnostic Impression with Formulation

D.A. is a 22-year-old Hispanic male patient with past medical history for mild intermittent asthma and no past history for any psychiatric disorder. He presents with long-term symptoms of fear of being judged in social settings. The clinical picture seen in D.A. fits the DSM-5-TR criteria for Social Anxiety Disorder (SAD) based on the presence of overwhelming fear of embarrassing himself, difficulty attending social occasions, and having anxiety when making presentations. These symptoms are resulting in considerable stress and impairment in the performance of his daily routine activities, including academics.

Risk Assessment

· Suicidal Ideation: D.A. denies having any thoughts, intentions, or plans about suicide.

· D.A. has no history of suicide attempts, and his risk is low.

· Homicidal Ideation: Denies any homicidal or violent ideation. Risk is low.

· Self-Harm: No history of non-suicidal self-injury. Risk is low.

· Overall Risk: Low risk.

· D.A. is stable and can be managed in the outpatient setting. He is also motivated to engage in treatment and has good family support.

Recommended Plan

Assessment and Screenings

· Liebowitz Social Anxiety Scale (LSAS).

· D.A. scored 62, which showed that he has moderate levels of social anxiety.

· PHQ-9 (Patient Health Questionnaire-9)

· D.A. scored 3, which showed very minimal depression symptom severity.

· GAD-7 (Generalized Anxiety Disorder 7-item scale).

· D.A. scored 11, which showed that his generalized anxiety symptoms were minimal.

· Laboratory tests that were ordered: None.

· Rationale: The patient’s current manifestation did not show any need to order laboratory testing.

Pharmacologic Management

1. Initiate Escitalopram 5 mg PO once daily for one week, then increase to 10 mg PO once daily as tolerated (Hjorth et al., 2022; Mitsui et al., 2022).

a. Rationale: Escitalopram is an SSRI and is considered first-line pharmacotherapy for social anxiety disorder. It works by increasing the amount of serotonin in the brain, which helps with the management of fear and social processing (Hjorth et al., 2022; Mitsui et al., 2022).

b. Escitalopram is chosen over other SSRIs due to its tolerability and efficacy when it comes to social anxiety disorder management (Hjorth et al., 2022; Mitsui et al., 2022).

c. Starting at 5 mg and titrating to 10 mg will help to reduce potential side effects, especially since the patient has never taken any psychotropic medications (Hjorth et al., 2022; Mitsui et al., 2022).

d. I would discuss the expected timeline for therapeutic effect with the patient, which is usually between one and two months.

Therapeutic Management

1. Refer to Cognitive Behavioral Therapy (CBT) with a licensed therapist (Papola et al., 2023).

a. Rationale: CBT is an effective psychotherapy for social anxiety disorder. It will focus on helping the patient to identify and change their maladaptive thought patterns. The patient will also learn suitable coping skills to deal with their anxiety in social situations (Kindred et al., 2022).

b. CBT also includes behavioral experiments and exposure exercises to help the patient gradually confront feared social situations (Kindred et al., 2022). 

Lifestyle and Psychosocial Interventions

1. Reduce caffeine intake to no more than 1 cup of coffee daily. 

a. Rationale: Caffeine is a stimulant that can directly increase anxiety symptoms, especially when taking in large amounts.

2. Implement regular physical activity. 

2. Rationale: Exercise has been shown to reduce anxiety and improve mood. It can also help with improving self-confidence (Knapik et al., 2026).

3. Maintain regular sleep with at least 8 hours of rest.

3. Rationale: A consistent sleep schedule, creating a relaxing bedtime routine, and avoiding screens in bed can help to reduce the possibility of developing insomnia and also help with anxiety reduction (Du et al., 2026).

4. Start gradual social engagements in low-anxiety situations.

4. Rationale: This will help with reducing avoidance behaviors in a gradual manner while also improving self-confidence when it comes to engaging with other people.

· I would discuss with the patient the option of joining a social skills group or a support group for individuals with social anxiety.  

Treatment Goals

1. D.A. will report a reduction in LSAS score by 50% within 12-16 weeks of treatment initiation.

2. D.A. will report a decrease in avoidance of social situations within 12 weeks.

3. D.A. will be able to attend at least one social event per week without significant distress within 12 weeks.

4. D.A. will go to the referred CBT therapist within 4 weeks.

5. D.A. will have improved academic performance due to reduced anxiety, including increased class participation, within 12 weeks.

Education and Consent

D.A. received education for social anxiety disorder, its symptoms, and the medications being used in the treatment plan. He gave full verbal consent for the treatment plan.

Follow Up

A follow-up was set after 2 weeks to evaluate Escitalopram effectiveness and considerations for increasing the dosage to 10 mg.

 

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th-TR). American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890425787

Du, Y., Wan, X., Xu, J., & Feng, H. (2026). The association between social anxiety and sleep among young people: A systematic review and meta-analysis. Child Psychiatry & Human Development. https://doi.org/10.1007/s10578-026-02003-9

Hjorth, O., Frick, A., Gingnell, M., Engman, J., Björkstrand, J., Faria, V., Alaie, I., Carlbring, P., Andersson, G., Jonasson, M., Lubberink, M., Antoni, G., Reis, M., Wahlstedt, K., Fredrikson, M., & Furmark, T. (2022). Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy. Translational Psychiatry, 12(1), 436. https://doi.org/10.1038/s41398-022-02187-3

Kindred, R., Bates, G. W., & McBride, N. L. (2022). Long-term outcomes of cognitive behavioral therapy for social anxiety disorder: A meta-analysis of randomized controlled trials. Journal of Anxiety Disorders, 92, 102640. https://doi.org/10.1016/j.janxdis.2022.102640

Knapik, A., Stadnicka, O., Brodowska, A., Kuś, J., Zięba, N., Czapiński, O., Tomicka, E., Ciesielski, M., Pysiewicz, M., & Białowąs, P. (2026). Physical exercise as a strategy for reducing social anxiety in young adults: A review of the evidence. Quality in Sport, 58, 72691. https://doi.org/10.12775/qs.2026.58.72691

Mitsui, N., Fujii, Y., Asakura, S., Imai, H., Yamada, H., Yoshinaga, N., Kanai, Y., Inoue, T., & Shimizu, E. (2022). Antidepressants for social anxiety disorder: A systematic review and meta‐analysis. Neuropsychopharmacology Reports, 42(4), 398–409. https://doi.org/10.1002/npr2.12275